Tumor escape from immune surveillance;Mecanismes d'echappement tumoral a la reponse immunitaire

Revue de Medecine Interne

Volumn 20, Issue 7, 1999, Pages 579-588

  Costello, R T ^a,b   Gastaut, J A ^b   Olive, D ^a,c  

^a Unite d'immunologie des tumeurs   (France)

^b INSTITUT PAOLI CALMETTES   (France)

^c INSERM   (France)

Author keywords

Cancer; Immunodeficiency; Immunotherapy; Lymphocyte

Indexed keywords

CD40 ANTIGEN; CYTOKINE; INTERLEUKIN 10; MAJOR HISTOCOMPATIBILITY ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; LYMPHOCYTE; MAJOR HISTOCOMPATIBILITY COMPLEX; TUMOR CELL; ANTIBODY PRODUCTION; CELLULAR IMMUNITY; HUMAN; IMMUNOLOGY; IMMUNOSURVEILLANCE; NEOPLASM; REVIEW; T LYMPHOCYTE;

ANTIBODY FORMATION; HUMANS; IMMUNITY, CELLULAR; IMMUNOLOGIC SURVEILLANCE; MAJOR HISTOCOMPATIBILITY COMPLEX; NEOPLASMS; T-LYMPHOCYTES;

EID: 0033165795     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(99)80107-6     Document Type: Article

References (116)

1. Korthauer U, Graf D, Mages HW, Briere F, Padayachee M, Malcolm S, et al. Detective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM. Nature 1993 ; 361 : 539-41.
2. Allen RC, Armitage RJ, Conley ME, Rosenblatt H, Jenkins NA, Copeland NG, et al. CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science 1993 ; 259 : 990-3.
3. Ramesh N, Fuleihan R, Ramesh V, Lederman S, Yellin MJ, Sharma S, et al. Deletions in the ligand for CD40 in X-linked immunoglobulin deficiency with normal or elevated IgM (HIGMX-1). Int Immunol 1993 ; 5 : 769-73.
4. Fuleihan R, Ramesh N, Loh R, Jabara H, Rosen RS, Chatila T, et al. Defective expression of the CD40 ligand in X chromosome-linked immunoglobulin deficiency with normal or elevated IgM. Proc Natl Acad Sci USA 1993 ; 90 : 2170-3.
5. Farrington M, Grosmaire LS, Nonoyama S, Fischer SH, Hollenbaugh D, Ledbetter JA, et al. CD40 ligand expression is defective in a subset of patients with common variable immunodeficiency. Proc Natl Acad Sci USA 1994 ; 91 : 1099-1103.
6. Swinnen LJ. Transplant immunosuppression-related malignant lymphomas. Cancer Treat Res 1993 ; 66 : 95-110.
7. Grierson H, Purtilo DT. Epstein-Barr virus infections in males with the X-linked lymphoproliferative syndrome. Ann Intern Med 1987 ; 106 : 538-45.
8. Posner JB. Paraneoplastic syndromes: A brief review. Ann N Y Acad Sci 1997 ; 835 : 83-90.
9. Schallreuter KU, Levenig C, Berger J. Vitiligo and cutaneous melanoma. Dermatologica 1991 ; 183 : 239-45.
10. Bystryn JC, Darrell R, Friedman RJ, Kopf A. Prognostic significance of hypopigmentation in malignant melanoma. Arch Dermatol 1987 ; 123 : 1053-5.
11. Koh HK, Sober AJ, Nakagawa H, Albert DM, Mihm MC, Fitzpatrick TB. Malignant melanoma and vitiligo-like leucoderma: An ekectron microscopy study. J Am Acad Dermatol 1983 ; 9 : 696-707.
12. Nordlund JJ, Kirkwood JM, Forget BM, Milton G, Albert DM, Lerner AB. Vitiligo in patients with metastatic melanoma: A good prognostic sign. J Am Acad Dermatol 1983 ; 9 : 689-96.
13. Richards JM, Mehta N, Ramming K, Skosey P. Sequential chemoimmunotherapy in the treatment of melastatic melanoma. J Clin Oncol 1992 ; 10 : 1338-43.
14. Scheibenbogen C, Hunstein W, Keilholz U. Vitiligo-like lesions following immunotherapy with IFNα and IL-2 in melanoma patients. Eur J Cancer 1994 ; 30A : 1209-11.
15. Alexander KR, Fishman GA, Peachey NS, Marchese AL, Tso MOM. "On" response defect in paraneoplastic night blindness with cutaneous malignant melanoma. Invest Ophthalmol Vis Sci 1992 ; 33 : 477-83.
16. Berson EL, Lessel S. Paraneoplastic night blindness with malignant melanoma. Am J Ophthalmol 1988 ; 106 : 307-11.
17. Kim RY, Retsas S, Fitzke SW, Arden GB, Bird AC. Cutaneous melanoma-associated retinopathy. Ophthalmology 1994 ; 101 : 1837-43.
18. Milam AH, Saari JC, Jacobson SG, Lubinski WP, Feun LG, Alexander KR. Autoantibodies against retinal bipolar cells in cutaneous melanoma-associated retinopathy. Invest Ophthalmol Vis Sci 1993 ; 34 : 91-100.
19. Ripps H, Carr RE, Siegel IM, Greenstein VC. Functional abnormalities in vincristine-induced night blindness. Invest Ophthalmol Vis Sci 1984 ; 25 : 787-94.
20. Rush JA. Paraneoplastic retinopathy in malignant melanoma. Am J Ophthalmol 1993 ; 115 : 390-1.
21. Singh AD, Milam AH, Shields CL, De Potter P, Shields JA. Melanoma-associated retinopathy. Am J Ophthalmol 1995 ; 119 : 369-70.
22. Cui J, Bystryn JC. Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells. Arch Dermatol 1995 ; 131 : 314-8.
23. Hartveit F. Breast cancer: Poor short-term prognosis in cases with moderate lymphocyte infiltration at the tumour edge: A preliminary report. Oncol Reports 1998 ; 5 : 423-6.
24. Oudejans JJ, Jiwa NM, Kummer JA, Ossenkoppele GJ, Van Heerde P, Baars JW, et al. Activated cytotoxic T cells as a prognostic marker in Hodgkin's disease. Blood 1997 ; 90 : 890-1.
25. Baur AS, Meuge-Moraw C, Michel G, Delacretaz F. Prognostic value of follicular dendritic cells in nodular sclerosing Hodgkin's disease. Histopathology 1998 ; 32 : 512-20.
26. Clemente CG, Mihm MCJ, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996 ; 77 : 1303-10.
27. Mihm MCJ, Clemente CG, Cascinelli N. Tumor infiltrating lymphocytes in lymph node melnoma metastases: A histopathologic prognostic indicator and an expression of local immun response. Lab Invest 1996 ; 74 : 43-7.
28. Costello R, Bouabdallah R, Sainty D, Gastaut JA, Gabert J. La leucémie myéloïde chronique, aspects biologiques. Rev Méd Interne 1996 ; 17 : 213-23.
29. Van den Eynde BJ, Van der Bruggen P. T cell defined tumor antigens. Curr Opin Immunol 1997 ; 9 : 684-93.
30. Anichini A, Maccalli C, Mortarini R, Salvi S, Mazzocchi A, Squarcina P, et al. Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients. J Exp Med 1993 ; 177 : 989-98.
31. Nagata Y, Furugen R, Hiasa A, Ikeda H, Ohta N, Furukawa K, et al. Peptides derived from a wild type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. J Immunol 1997 ; 159 : 1336-43.
32. Gu X-G, Schmitt M, Hiasa A, Nagata Y, Ikeda H, Sasaki H, et al. A novel hydrophobized polysacharide/oncoprotein complex vaccine induces in vitro and in vivo cellular and humoral immune responses against HER2-expressing murine sarcomas. Cancer Res 1998 ; 58 : 3385-90.
33. Ressing ME, Sette A, Brandt RMP, Ruppert J, Wentworth PA, Hartman M, et al. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol 1995 ; 154 : 5934-43.
34. Cromme FV, Airey J, Heemels MT, Ploegh HL, Keating PJ, Stern PL, et al. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med 1994 ; 179 : 335-40.
35. Sanda MG, Restifo NP, Walsh JC, Kawakami Y, Nelson WG, Pardoll DM, et al. Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst 1995 ; 87 : 280-5.
36. Restifo NP, Esquivel F, Kawakami Y, Yewdell JW, Mule JJ, Rosenberg SA, et al. Identification of human cancers deficient in antigen processing. J Exp Med 1993 ; 177 : 265-72.
37. Korkolopoulou P, Kaklamanis L, Pezzella F, Harris AL, Gatter KC. Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. Br J Cancer 1996 ; 73 : 148-53.
38. Rowe M, Khanna R, Jacob CA, Argaet V, Kelly A, Powis S, et al. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: Coordinate up-regulation of peptide transporters and HLA-class I antigen expression. Eur J Immunol 1995 ; 25 : 1374-84.
39. Jakobsen MK, Restifo NP, Cohen PA, Marincola FM, Cheshire LB, Linehan WM, et al. Defective major histocompatibility complex class I expression in a sarcomatoid renal cell carcinoma cell line. J Immunother Emphasis Tumor Immunol 1995 ; 17 : 222-8.
40. Kaklamanis L, Gatter KC, Hill AB, Mortensen N, Harris AL, Krausa P, et al. Loss of HLA class-I alleles, heavy chains and beta 2-microglobulin in colorectal cancer. Int J Cancer 1992 ; 51 : 379-85.
41. Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yannelli JR, Rosenberg SA. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 1996 ; 88 : 100-8.
42. Porgador A, Mandelboim O, Restifo NP, Strominger JL. Natural killer cell lines kill autologous beta2-microglobulin-deficient melanoma cells: Implications for cancer immunotherapy. Proc Natl Acad Sci USA 1997 ; 94 : 13140-5.
43. Kaklamanis L, Leek R, Koukourakis M, Gatter KC, Harris AL. Loss of transporter in antigen processing 1 transport protein and major histocompatibility complex class I molecules in metastatic versus primary breast cancer. Cancer Res 1995 ; 55 : 5191-4.
44. Guinan EC, Gribben JG, Boussiotis VA, Freeman GJ, Nadler LM. Pivotal role of the B7: CD28 pathway in transplantation tolerance and tumor immunity. Blood 1994 ; 84 : 3261-82.
45. Olive D, Pages F, Klasen S, Battifora M, Costello R, Nunes J, et al. Stimulation via the CD28 molecule. Regulation of signalling, cytokine production and cytokine receptor expression. Fundam Clin Immunol 1994 ; 2 : 185-97.
46. Schultze J, Nadler LM, Gribben JG. B7-mediated costimulation and the immune response. Blood Rev 1996 ; 10 : 111- 27.
47. Olive D, Van Lier R. CD28 and T-cell activation. Res Immunol 1995 ; 146 : 127-9.
48. Cerdan C, Costello R, Collette Y, Mawas C, Olive D. Co-stimulation of T-cell Immune Response: A Potential Role in Tumor Immunology.Paris: Inserm: 1998. p. 151-72.
49. Dorfman DM, Schultze J, Shahsafaei A, Michalak S, Gribben JG, Freeman GJ, et al. In vivo expression of B7-1 and B7-2 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation. Blood 1997 ; 90 : 4297-306.
50. Van den Hove LE, Van Goll SW, Vandenberghe P, Bakkus M, Thielemans K, Boogaerts MA, et al. CD40 triggering of chronic lymphocytic leukemia B cells results in efficient alloantigen presentation and cytotoxic T lymphocyte induction by up-regulation of CD80 and CD86 costimulatory molecules. Leukemia 1997 ; 11 : 572-80.
51. Plumas J, Chaperot L, Jacob MC, Molens JP, Giroux C, Sotto JJ, et al. Malignant B lymphocytes from non-Hodgkin's lymphoma induce allogeneic proliferative and cytotoxic T cell responses in primary mixed lymphocyte cultures: An important role of co-stimulatory molecules CD80 (B7-1) and CD86 (B7-2) in stimulation by tumor cells. Eur J Immunol 1995 ; 25 : 3332-41.
52. Munro JM, Freedman AS, Aster JC, Gribben JG, Lee NC, Rhynhart KK, et al. In vivo expression of the B7 costimulatory molecule by subsets of antigen-presenting cells and the malignant cells of Hodgkin's disease. Blood 1994 ; 83 : 793-8.
53. Delabie J, Ceuppens JL, Vandenberghe P, De Boer M, Coorevits L, De Wolf-Peeters C. The B7/BB1 antigen is expressed by ReedSternberg cells of Hodgkin's disease and contributes to the stimulating capacity of Hodgkin's disease-derived cell lines. Blood 1993 ; 82 : 2845-52.
54. Hirano N, Takahashi T, Ohtake S, Hirashima K, Emi N, Saito K, et al. Expression of costimulatory molecules in human leukemias. Leukemia 1996 ; 10 : 1168-76.
55. Costello RT, Mallet F, Sainty D, Maraninchi D, Gastaut JA, Olive D. Regulation of CD80/B7-1 and CD86/B7-2 molecule expression in human primary acute myeloid leukemia and their role in aliogenic immune recognition. Eur J Immunol 1998 ; 28 : 90-103.
56. Tsukada N, Aoki S, Maruyama S, Kishi K, Takahashi M, Aizawa Y. The heterogeneous expression of CD80, CD86 and other adhesion molecules on leukemia and lymphoma cells and their induction by interferon. J Exp Clin Can Res 1997 ; 16 : 171-6.
57. Linsley PS, Ledbetter J, Peach R, Bajorath J. CD28/CTLA-4 receptor structure, binding stoichiometry and aggregation during T-cell activation. Res Immunol 1995 ; 146 : 130-40.
58. Gribben JG, Freeman GJ, Boussiotis VA, Rennen P, Jellis CL, Greenfield E, et al. CTLA4 mediates antigen-specific apoptosis of human T cells. Proc Natl Acad Sci USA 1995 ; 92 : 811-5.
59. Strand S, Galle PR. Immune evasion by tumours: Involvement of the CD95 (APO-1/Fas) system and its clinical implications. Mol Med Today 1998 ; 4 : 63-8.
60. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996 ; 184 : 1075-82.
61. Strand S, Hofmann WJ, Hug H, Müller M, Otto G, Strand D, et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells. A mechanism of immune evasion? Nature Med 1996 ; 2 : 1361-6.
62. Hahne M, Rimoldi D, Schröter M, Romero P, Schreier M, French LE, et al. Melanoma cell expression of Fas (Apo-1/Cd95) ligand: Implications for tumor immune escape. Science 1996 ; 274 : 1363-6.
63. Xerri L, Devilard E, Hassoun J, Haddad P, Birg F. Malignant and reactive cells from human lymphomas frequently express Fas ligand but display a different sensitivity to Fas-mediated apoptosis. Leukemia 1997 ; 11 : 1868-77.
64. Plumas J, Jacob MC, Chaperot L, Molens JP, Sotto JJ, Bensa JC. Tumor B cells from non-Hodgkin's lymphoma are resistant to CD95 (Fas/Apo-1)-mediated apoptosis. Blood 1998 ; 91 : 2875-85.
65. Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F, et al. Fas ligand in human serum. Nature Med 1996 ; 2 : 317-22.
66. Tanaka M, Itai T, Adachi M, Nagata S. Downregulation of Fas ligand by shedding. Nature Med 1998 ; 4 : 31-6.
67. Banchereau J, Bazan F, Blanchard D, Briere F, Galizzi JP, Van Kooten C, et al. The CD40 antigen and its ligand. Annu Rev Immunol 1994 ; 12 : 881-922.
68. Grüss H-J, Dower SK. Tumor necrosis factor ligand superfamily: Involvement in the pathology of malignant lymphomas. Blood 1995 ; 85 : 3378-3404.
69. Cantwell M, Hua T, Pappas J, Kipps TJ. Acquired CD40-ligand deficiency in chronic lymphocytic leukemia. Nature Med 1997 ; 3 : 984-9.
70. Musiani P. Cytokines, tumour cell-death and immunogenicity: A question of choice. Immunol Today 1997 ; 18 : 32-6.
71. Ljunggren HG, Karre K. In search of the "missing self": MHC molecules and NK cell recognition. Immunol Today 1990 ; 12 : 237-44.
72. Scott AM, Welt S. Antibody-based immunological therapies. Curr Opin Immunol 1997 ; 9 : 717-22.
73. Maloney DG, Grillo-Lopez A, White CA, Bodkin D, Schilder RJ, Neidhart JA, et al. IDEC-C2B8 (Rituximab) anti-Cd20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997 ; 90 : 2188-95.
74. Maloney DG, Grillo-Lopez A, Bodkin D, White CA, Liles T-M, Royston I, et al. IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997 ; 15 : 3266-74.
75. Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, et al. Phase 1 clinical trial using escalating single-dose infusion of chimeric anti-Cd20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994 ; 84 : 2457-66.
76. Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 1998 ; 92 : 1927-32.
77. Olive D, Chambost H, Sainty D, Stoppa A-M, Blaise D, El Marsafy S, et al. Modifications of leukemic blast cells induced by in vivo high-dose recombinant interleukin-2. Leukemia 1994 ; 8 : 1230-5.
78. Herberman RB. Effects of a-interferons on immune functions. Semin Oncol 1997 ; 24 Suppl 9 : 78-80.
79. Costello R, Lipcey C, Olive D. Rationale for the utilization of interleukin-4, an immune-recognition induced cytokine, in cancer immunotherapy. Eur J Med 1993 ; 2 : 54-7.
80. Costello R, Imbert J, Olive D. Interleukin-7, a major T-lymphocyte cytokine. Eur Cytokine Netw 1993 ; 4 : 253-62.
81. Schultze JL, Cardoso AA, Freeman GJ, Seamon MJ, Daley J, Pinkus GS, et al. Follicular lymphomas can be induced to present alloantigen efficiently: A conceptual model to improve their tumor immunogenicity. Proc Natl Acad Sci USA 1995 ; 92 : 8200-4.
82. Schultze JL, Seamon MJ, Michalak S, Gribben JG, Nadler LM. Autologous tumor infiltrating T cells cytotoxic for follicular lymphoma cells can be expanded in vitro. Blood 1997 ; 89 : 3806-16.
83. Khanna R, Cooper L, Kienzle N, Moss DJ, Burrows SR, Khanna KK. Cutting edge: Engagement of CD40 antigen with soluble CD40 ligand up-regulates peptide transporter expression and restores endogenous processing function in Burkitt's lymphoma cells. J Immunol 1997 ; 159 : 5782-5.
84. Andersson ML, Stam NJ, Klein G, Ploegh HL, Masucci MG. Aberrant expression of HLA class-I antigens in Burkitt lymphoma cells. Int J Cancer 1991 ; 47 : 544-9.
85. Gruss HJ, Hirschstein D, Wright B, Ulrich D, Caligiuri MA, Barcos M, et al. Expression and function of CD40 on Hodgkin and reed-sternberg cells and the possible relevance for Hodgkin's disease. Blood 1994 ; 84 : 2305-14.
86. Mackensen A, Lindemann A, Mertelsmann R. Immunostimulatory Cytokines in Somatic Cell and Gene Therapy. Paris: Inserm: 1998 ; 24 : 461-74.
87. Mukherjee B, Chakraborty NG, Yamasaki S, Okino T, Yamase T, Sporn J, et al. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci USA 1995 ; 92 : 8082.
88. Marchand M, Weynants P, Rankin E, Arienti F, Belli F, Parmiani G, et al. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 1995 ; 63 : 883-5.
89. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Med 1998 ; 4 : 328-32.
90. Rosenbeg SA, Yang J-C, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med 1998 ; 4 : 321-7.
91. Lode HN, Xiang R, Dreier T, Varki NM, Gillies SD, Reisfeld RA. Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood 1998 ; 91 : 1706-15.
92. Moretta A, Sivori S, Ponte M, Mingari MC, Moretta L. Stimulatory receptors in NK and T cells. Curr Topics Microbiol Immunol 1998 ; 230 : 15-23.
93. Whiteside TL, Vujanovic NL, Herberman RB. Natural killer cells and tumor therapy. Curr Topics Microbiol Immunol 1998 ; 230 : 221-44.
94. Granel B, Vivier E. Les cellules NK: Biologie, modes de régulation et interêt clinique. Hématologie 1998 ; 4 : 41-9.
95. Restifo NP, Kawakami Y, Marincola F, Shamamian P, Taggarse A, Esquivel F, et al. Molecular mechanisms used by tumors to escape immune recognition: Immunogenetherapy and the cell biology of major histocompatibility complex class I. J Immunother 1993 ; 14 : 182-90.
96. Rivoltini L, Barracchini KC, Viggiano V, Kawakami Y, Smith A, Mixon A, et al. Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. Cancer Res 1995 ; 55 : 3149-57.
97. Morse MA, Lyerly HK. Immunotherapy of cancer using dendritic cells. Cytokines Cell Mol Ther 1998 ; 4 : 35-44.
98. Lotze MT, Hellerstedt B, Stolinski L, Tueting T, Wilson C, Kinzler D, et al. The role of interleukin-2, interleukin-12, and dendritic cells in cancer therapy. Cancer J Scientific Am 1997 ; 3 Suppl 1 : S109-14.
99. Engleman EG. Dendritic cells: Potential role in cancer therapy. Cytotechnology 1997 ; 25 : 1-8.
100. Alters SE, Gadea JR, Philip R. Immunotherapy of cancer. Generation of CEA specific CTL using CEA peptide pulsed dendritic cells. Adv Exp Med Biol 1997 ; 417 : 519-24.
101. Thurnher M, Papesh C, Ramoner R, Gastl G, Bock G, Radmayr C, et al. In vitro generation of CD83+ human blood dendritic cells for active tumor immunotherapy. Exp Hematol 1997 ; 25 : 232-7.
102. Hermans IF, Moroni-Rawson P, Ronchese F, Ritchie DS. The emerging role of the dendritic cell in novel cancer therapies. N Z Med J 1998 ; 111 : 111-3.
103. Kennedy MK, Mohler KM, Shanebeck KD, Baum PR, Picha KS, Otten-Evans CA, et al. Induction of B cell costimulatory function by recombinant murine CD40 ligand. Eur J Immunol 1994 ; 24 : 116-23.
104. Chen Y-T, Stocken E, Tsang S, Coplan KA, Old LJ. Immunophenotyping of melanomas for tyrosinase: Implications for vaccine development. Proc Natl Acad Sci USA 1995 ; 92 : 8125-9.
105. Jäger E, Ringhoffer M, Karbach J, Arand M, Oesch F, Knuth A. Inverse relationship of melanocyte differentiation antigen expression in melanoma: Evidence for immunoselection of antigen-loss variant in vivo. Int J Cancer 1996 ; 67 : 470-6.
106. Wakahara Y, Nawa A, Okamoto T, Hayakawa A, Kikkawa F, Suganama N, et al. Combination effect of anti-Fas antibody and chemotherapeutic drugs in ovarian cancer cells in vitro. Oncology 1997 ; 54 : 48-54.
107. Kitada S, Takayama S, De Riel K, Tanaka S, Reed JC. Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. Antisense Res Dev 1994 ; 4 : 71-9.
108. Roncella S, Cutrona G, Favre A, Ulivi M, Fais F, Signorini A, et al. Apoptosis of Burkitt's lymphoma cells induced by specific interaction of surface IgM with a self-antigen: Implications for lymphomagenesis in acquired immunodeficiency syndrome. Blood 1996 ; 88 : 599-608.
109. Wang D, Freeman GJ, Levine H, Ritz J, Robertson MJ. Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies. Br J Haematol 1997 ; 97 : 409-17.
110. Weiss T, Grell M, Hessabi B, Bourteele S, Muller G, Scheurich P, et al. Enhancement of TNF receptor p60-mediated cytotoxicity by TNF receptor p80: Requirement of the TNF receptor-associated factor-2 binding site. J Immunol 1997 ; 158 : 2398-2404.
111. Hess S, Engelmann H. A novel function of CD40: Induction of cell death in transformed cells. J Exp Med 1996 ; 183 : 159-67.
112. Ware CF, Vanarsdale S, Vanarsdale TL. Apoptosis mediated by the TNF-related cytokine and receptor families. J Cell Biochem 1996 ; 60 : 47-55.
113. Enari M, Hug H, Hayakawa M, Ito F, Nishimura Y, Nagata S. Different apoptotic pathways mediated by Fas and the tumornecrosis-factor receptor. Cytosolic phospholipase A2 is not involved in Fas-mediated apoptosis. Eur J Biochem 1996 ; 236 : 533-8.
114. Baker SJ, Reddy EP. Transducers of life and death: TNF receptor superfamily and associated proteins. Oncogene 1996 ; 12 : 1-9.
115. Bodmer J-L, Burns K, Schneider P, Hofmann K, Steiner V, Thome M et al. TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis factor receptor 1 and Fas (Apo-1/CD95). Immunity 1997 ; 6 : 79-88.
116. Nagata S. Apoptosis by death factor. Cell 1997 ; 88 : 355-65.